







an Open Access Journal by MDPI

# Metabolomics and Biomarker Discovery and Evaluation: The New Frontier in the Screening, Diagnosis and Therapeutic Monitoring of Inborn Errors of Metabolism

Guest Editor:

#### Dr. Mohamed A. Elmonem

Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo 11628, Egypt

Deadline for manuscript submissions:

closed (20 December 2023)

# **Message from the Guest Editor**

In this Special Issue of *Metabolites* we welcome research proposals which include but are not limited to the following topics:

- Metabolomics techniques and approaches for clinical purposes;
- Targeted vs. untargeted metabolomics in inborn errors of metabolism:
- Biomarker discovery and validation for the screening and diagnosis of inborn errors of metabolism;
- Biomarker discovery and validation for the therapeutic monitoring of inborn errors of metabolism:
- Phenotype correlation with novel biomarkers in inborn errors of metabolism;
- Genotype correlation with novel biomarkers in inborn errors of metabolism;
- Genetics vs. metabolomics for the screening of inborn errors of metabolism.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy 2. Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

# **Message from the Editor-in-Chief**

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies shown utility elucidating have for mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Biochemistry and Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

## **Contact Us**